UB Paderborn / Katalog / Suche / in CDI

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

The Lancet (British edition), 2020-05, Vol.395 (10236), p.1547-1557

2020

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma

Clinical Medicine Insights. Oncology, 2022, Vol.16, p.117955492211262-11795549221126252

2022

Link zum Volltext

Verfügbarkeit prüfen

Characterization and Survival Benefit of Drug Approvals for Metastatic Prostate Cancer, 2004 to 2022

Clinical Medicine Insights. Oncology, 2024-01, Vol.18, p.11795549241227413-11795549241227413

2024

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

The lancet oncology, 2022-02, Vol.23 (2), p.248-258

2022

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant pembrolizumab in genomically selected high-risk patients with muscle-invasive bladder cancer

Journal of oncology pharmacy practice, 2021-12, Vol.27 (8), p.2053-2056

2021

Link zum Volltext

Verfügbarkeit prüfen

Prostate Cancer in Sexual Minorities: Epidemiology, Screening and Diagnosis, Treatment, and Quality of Life

Cancers, 2023-05, Vol.15 (9), p.2654

2023

Link zum Volltext

Verfügbarkeit prüfen

Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice

Cancer treatment reviews, 2021-06, Vol.97, p.102187-102187, Article 102187

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial

Journal for immunotherapy of cancer, 2022-02, Vol.10 (2), p.e003844

2022

Link zum Volltext

Verfügbarkeit prüfen

Circadian Clock Dysregulation and Prostate Cancer: A Molecular and Clinical Overview

Clinical Medicine Insights. Oncology, 2023-01, Vol.17, p.11795549231211521-11795549231211521

2023

Link zum Volltext

Verfügbarkeit prüfen

Treatment approaches for urachal cancer: Use of immunotherapy and targeted therapies

Rare Tumors, 2023-01, Vol.15, p.20363613231189984-20363613231189984

2023

Link zum Volltext

Verfügbarkeit prüfen

Diversifying editorial boards to mitigate the global burden of genitourinary cancers

Nature reviews. Urology, 2024-03

2024

Link zum Volltext

Verfügbarkeit prüfen

Patient preferences in the treatment of genitourinary cancers

Nature reviews. Urology, 2023-09, Vol.20 (9), p.513-514

2023

Link zum Volltext

Verfügbarkeit prüfen

Spontaneous Regression of Delayed Pulmonary and Mediastinal Metastases from Clear Cell Renal Cell Carcinoma

Case reports in oncology, 2020-10, Vol.13 (3), p.1285-1294

2020

Link zum Volltext

Verfügbarkeit prüfen

Examining the relationship between strategic alliances and the performance of small entrepreneurial firms in telecommunications

International entrepreneurship and management journal, 2022-06, Vol.18 (2), p.637-662

2022

Link zum Volltext

Verfügbarkeit prüfen

Drug extravasation with Enfortumab vedotin

Journal of oncology pharmacy practice, 2023-10, Vol.29 (7), p.1789-1792

2023

Link zum Volltext

Verfügbarkeit prüfen

A comparative study of spinal cord compression management in metastatic prostate cancer: Teaching versus non‐teaching hospitals in the United States

Cancer medicine (Malden, MA), 2024-01, Vol.13 (1), p.n/a

2024

Link zum Volltext

Verfügbarkeit prüfen

Use of immunotherapy in clinical management of genitourinary cancers – a review

Cancer treatment and research communications, 2022, Vol.31, p.100564-100564, Article 100564

2022

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial

BMJ open, 2022-09, Vol.12 (9), p.e058396-e058396

2022

Link zum Volltext

Verfügbarkeit prüfen

Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma

Case reports in oncology, 2021-07, Vol.14 (2), p.1051-1058

2021

Link zum Volltext

Verfügbarkeit prüfen

Renal Cell Carcinoma-Lessons in Diversity, Breakthroughs, and Challenges

JCO oncology practice, 2022-03, Vol.18 (3), p.197-199

2022

Link zum Volltext

Verfügbarkeit prüfen

Cardiac Stem Cells Delivered Intravascularly Traverse the Vessel Barrier, Regenerate Infarcted Myocardium, and Improve Cardiac Function

Proceedings of the National Academy of Sciences - PNAS, 2005-03, Vol.102 (10), p.3766-3771

2005

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920

Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma

Characterization and Survival Benefit of Drug Approvals for Metastatic Prostate Cancer, 2004 to 2022

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

Adjuvant pembrolizumab in genomically selected high-risk patients with muscle-invasive bladder cancer

Prostate Cancer in Sexual Minorities: Epidemiology, Screening and Diagnosis, Treatment, and Quality of Life

Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial

Circadian Clock Dysregulation and Prostate Cancer: A Molecular and Clinical Overview

Treatment approaches for urachal cancer: Use of immunotherapy and targeted therapies

Diversifying editorial boards to mitigate the global burden of genitourinary cancers

Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study

Patient preferences in the treatment of genitourinary cancers

Spontaneous Regression of Delayed Pulmonary and Mediastinal Metastases from Clear Cell Renal Cell Carcinoma

Examining the relationship between strategic alliances and the performance of small entrepreneurial firms in telecommunications

Drug extravasation with Enfortumab vedotin

A comparative study of spinal cord compression management in metastatic prostate cancer: Teaching versus non‐teaching hospitals in the United States

Use of immunotherapy in clinical management of genitourinary cancers – a review

Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma-Lessons in Diversity, Breakthroughs, and Challenges

Cardiac Stem Cells Delivered Intravascularly Traverse the Vessel Barrier, Regenerate Infarcted Myocardium, and Improve Cardiac Function

Suchergebnisse filtern